|
|
|
|
|
|
Late |
Ader et al., Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00485-0 (Peer Reviewed) |
death, ↓6.4%, p=0.77 |
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial |
|
Details
RCT 857 hospitalized patients, showing no significant differences with remdesivir treatment. DISCOVERY trial. EudraCT2020-000936-23, NCT04315948. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Ader et al., Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00485-0 (Peer Reviewed) |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial |
RCT 857 hospitalized patients, showing no significant differences with remdesivir treatment. DISCOVERY trial. EudraCT2020-000936-23, NCT04315948.
![]()
risk of death, 6.4% lower, RR 0.94, p = 0.77, treatment 34 of 414 (8.2%), control 37 of 418 (8.9%), adjusted, OR converted to RR, 28 days.
risk of 7-point scale status, 9.9% lower, RR 0.90, p = 0.39, treatment 414, control 418, 28 days, RR approximated with OR.
risk of 7-point scale status, 2.0% higher, RR 1.02, p = 0.85, treatment 414, control 418, 15 days, RR approximated with OR.
Ader et al., 9/14/2021, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 17 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Diaz et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab698 (Peer Reviewed) |
death, ↓34.7%, p=0.01 |
Remdesivir and Mortality in Patients with COVID-19 |
|
Details
Retrospective 1138 hospitalized patients in the USA, 286 treated with remdesivir, showing lower mortality with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Diaz et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab698 (Peer Reviewed) |
| Remdesivir and Mortality in Patients with COVID-19 |
Retrospective 1138 hospitalized patients in the USA, 286 treated with remdesivir, showing lower mortality with treatment.
![]()
risk of death, 34.7% lower, RR 0.65, p = 0.01, treatment 33 of 286 (11.5%), control 173 of 852 (20.3%), adjusted, OR converted to RR, multivariable Cox proportional-hazards.
Diaz et al., 8/19/2021, retrospective, USA, North America, peer-reviewed, 45 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Eldeen et al., Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177 (Peer Reviewed) |
Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19 hospitalized patients |
|
Details
Small study comparing 25 HCQ and 25 remdesivir hospitalized patients, reporting faster viral clearance with remdesivir. The article proof is missing the results for the HCQ group. Confounding by time is likely - remdesivir patients were a.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Eldeen et al., Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177 (Peer Reviewed) |
| Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19 hospitalized patients |
|
Small study comparing 25 HCQ and 25 remdesivir hospitalized patients, reporting faster viral clearance with remdesivir. The article proof is missing the results for the HCQ group. Confounding by time is likely - remdesivir patients were after HCQ patients in time, and treatment protocols improved over the period of the study.
Eldeen et al., 8/16/2021, peer-reviewed, 5 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Hosseini et al., medRxiv, doi:10.1101/2021.08.13.21261992 (Preprint) |
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial |
|
Details
Single arm remdesivir trial with 145 hospitalized patients showing no statistically significant difference between "early" and "late" administration, however the treatment delays may be better described as late and ver.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Hosseini et al., medRxiv, doi:10.1101/2021.08.13.21261992 (Preprint) |
| Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial |
Single arm remdesivir trial with 145 hospitalized patients showing no statistically significant difference between "early" and "late" administration, however the treatment delays may be better described as late and very late. The text of the paper defines early and late as less than or more than 7 days from symptom onset, however the CONSORT diagram says during or after 7 days post admission.
![]()
Hosseini et al., 8/13/2021, preprint, 15 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Kuno et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab256 (Peer Reviewed) |
death, ↓0.9%, p=0.96 |
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids
|
|
Details
PSM retrospective 3,372 hospitalized patients in the USA treated with steroids, showing no significant difference in mortality with remdesivir, but a lower risk of acute kidney injury. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Kuno et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab256 (Peer Reviewed) |
| The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids
|
PSM retrospective 3,372 hospitalized patients in the USA treated with steroids, showing no significant difference in mortality with remdesivir, but a lower risk of acute kidney injury.
![]()
risk of death, 0.9% lower, RR 0.99, p = 0.96, treatment 214 of 999 (21.4%), control 216 of 999 (21.6%), PSM.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 140 of 999 (14.0%), control 140 of 999 (14.0%), PSM.
risk of ICU admission, 17.1% higher, RR 1.17, p = 0.05, treatment 260 of 999 (26.0%), control 222 of 999 (22.2%), PSM.
Kuno et al., 8/9/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
Meta |
Anseems et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD014962 (Preprint) (meta analysis) |
meta-analysis |
Remdesivir for the treatment of COVID‐19 |
|
Details
Review of 5 RCTs prior to April 17, 2021 showing mortality RR 0.93 [0.81-1.06] for hospitalized patients. |
|
Details
Source
PDF
Meta
Meta
|
| Anseems et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD014962 (Preprint) (meta analysis) |
| Remdesivir for the treatment of COVID‐19 |
|
Review of 5 RCTs prior to April 17, 2021 showing mortality RR 0.93 [0.81-1.06] for hospitalized patients.
Anseems et al., 8/5/2021, preprint, 10 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600 (Preprint) |
death, ↓44.4%, p=0.03 |
Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir |
|
Details
Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Madan et al., medRxiv, doi:10.1101/2021.07.15.21260600 (Preprint) |
| Remdesivir for the treatment of COVID-19 disease: A retrospective comparative study of patients treated with and without Remdesivir |
Retrospective 1,262 hospitalized patients, 398 treated with remdesivir, showing unadjusted lower mortality with treatment, and a treatment delay-response relationship.
![]()
risk of death, 44.4% lower, RR 0.56, p = 0.03, treatment 23 of 398 (5.8%), control 27 of 260 (10.4%), unadjusted.
risk of death, 65.6% lower, RR 0.34, p = 0.04, treatment 4 of 112 (3.6%), control 27 of 260 (10.4%), unadjusted, <5 days from onset.
risk of death, 61.7% lower, RR 0.38, p = 0.009, treatment 9 of 226 (4.0%), control 27 of 260 (10.4%), unadjusted, 5-10 days from onset.
risk of death, 60.5% higher, RR 1.60, p = 0.18, treatment 10 of 60 (16.7%), control 27 of 260 (10.4%), unadjusted, >10 days from onset.
Madan et al., 7/19/2021, retrospective, India, South Asia, preprint, 22 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Ohl et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741 (Peer Reviewed) |
death, ↑6.0%, p=0.66 |
Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19 |
|
Details
Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Ohl et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.14741 (Peer Reviewed) |
| Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19 |
Retrospective 5,898 hospitalized patients in the USA, 2,374 receiving remdesivir treatment, showing no significant difference in mortality, and a longer time to hospital discharge with treatment.
![]()
risk of death, 6.0% higher, RR 1.06, p = 0.66, treatment 143 of 1172 (12.2%), control 124 of 1172 (10.6%), adjusted, PSM, Cox proportional hazards regression.
hospitalization time, 100% higher, relative time 2.00, p < 0.001, treatment 1172, control 1172, PSM, Cox proportional hazards regression.
Ohl et al., 7/15/2021, retrospective, propensity score matching, USA, North America, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653 (Peer Reviewed) |
death, 0.0%, p=1.00 |
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 |
|
Details
Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653 (Peer Reviewed) |
| Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 |
Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616.
risk of death, no change, RR 1.00, p = 1.00, treatment 3 of 37 (8.1%), control 4 of 53 (7.5%), adjusted.
Barrat-Due et al., 7/13/2021, Double Blind Randomized Controlled Trial, Norway, Europe, peer-reviewed, 41 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Arch et al., medRxiv, doi:10.1101/2021.06.18.21259072 (Preprint) |
death, ↓19.9%, p=0.03 |
Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study |
|
Details
Prospective PSM analysis of remdesivir use in the UK showing statistically significantly lower mortality at 28 days. For unspecified reasons, the study prioritized short-term outcomes. Mortality at 14 days was also lower but not statistic.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Arch et al., medRxiv, doi:10.1101/2021.06.18.21259072 (Preprint) |
| Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study |
Prospective PSM analysis of remdesivir use in the UK showing statistically significantly lower mortality at 28 days. For unspecified reasons, the study prioritized short-term outcomes. Mortality at 14 days was also lower but not statistically significant. Confounding by indication is likely and may only be partially addressed by the variables included in the PSM.
![]()
risk of death, 19.9% lower, RR 0.80, p = 0.03, treatment 203 of 1491 (13.6%), control 777 of 4676 (16.6%), OR converted to RR, 28 days, PSM.
risk of death, 18.0% lower, RR 0.82, p = 0.12, treatment 140 of 1502 (9.3%), control 565 of 4728 (12.0%), OR converted to RR, 28 days, PSM.
risk of mechanical ventilation, 68.0% higher, RR 1.68, p = 0.003, treatment 106 of 1498 (7.1%), control 153 of 4602 (3.3%), OR converted to RR, 28 days, PSM.
Arch et al., 6/21/2021, prospective, propensity score matching, United Kingdom, Europe, preprint, 10 authors.
|
|
Submit Corrections or Comments
|
|
Meta |
Liao et al., Journal of the Formosan Medical Association, doi:10.1016/j.jfma.2021.04.026 (Peer Reviewed) (meta analysis) |
meta-analysis |
Assessing Efficacy of Antiviral Therapy for COVID-19 Patients: A Case Study on Remdesivir with Bayesian Synthesis Design and Multistate Analysis |
|
Details
Bayesian synthesis design and multistate analysis of remdesivir results showing 31% [18-44%] lower risk of death and 10% [1-18%] higher recovery. |
|
Details
Source
PDF
Meta
Meta
|
| Liao et al., Journal of the Formosan Medical Association, doi:10.1016/j.jfma.2021.04.026 (Peer Reviewed) (meta analysis) |
| Assessing Efficacy of Antiviral Therapy for COVID-19 Patients: A Case Study on Remdesivir with Bayesian Synthesis Design and Multistate Analysis |
Bayesian synthesis design and multistate analysis of remdesivir results showing 31% [18-44%] lower risk of death and 10% [1-18%] higher recovery.
![]()
Liao et al., 5/4/2021, peer-reviewed, 7 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 (Peer Reviewed) |
death, ↓18.6%, p=0.49 |
Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19 |
|
Details
Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Aghajani et al., Journal of Medical Virology, doi:10.1002/jmv.27053 (Peer Reviewed) |
| Decreased In-Hospital Mortality Associated with Aspirin Administration in Hospitalized Patients Due to Severe COVID-19 |
Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results for HCQ, remdesivir, and favipiravir.
risk of death, 18.6% lower, RR 0.81, p = 0.49, treatment 46, control 945, univariate Cox proportional regression.
Aghajani et al., 4/29/2021, retrospective, Iran, Middle East, peer-reviewed, 7 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Mulhem et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 (Peer Reviewed) |
death, ↑85.7%, p=0.54 |
3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study |
|
Details
Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Mulhem et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 (Peer Reviewed) |
| 3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study |
Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06 [2.44-3.83]) suggest significant confounding by indication and confounding by time.
risk of death, 85.7% higher, RR 1.86, p = 0.54, treatment 1 of 8 (12.5%), control 515 of 3211 (16.0%), adjusted, OR converted to RR, logistic regression.
Mulhem et al., 4/7/2021, retrospective, database analysis, USA, North America, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21 (Peer Reviewed) |
death, ↑76.5%, p=0.47 |
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study |
|
Details
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21 (Peer Reviewed) |
| Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study |
Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.
![]()
risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).
risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).
Mahajan et al., 3/20/2021, Randomized Controlled Trial, India, South Asia, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Tsuzuki et al., medRxiv, doi:10.1101/2021.03.09.21253183 (Preprint) |
death, ↓8.8%, p=1.00 |
Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan |
|
Details
Retrospective database analysis of 1907 hospitalized patients in Japan, using PSM to compare 74 remdesivir patients and 195 control patients, not showing significant differences in mortality and ventilation/ECMO, and showing signifcantly .. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Tsuzuki et al., medRxiv, doi:10.1101/2021.03.09.21253183 (Preprint) |
| Efficacy of remdesivir in Japanese patients hospitalised with COVID-19: A large observational study using the COVID-19 Registry Japan |
Retrospective database analysis of 1907 hospitalized patients in Japan, using PSM to compare 74 remdesivir patients and 195 control patients, not showing significant differences in mortality and ventilation/ECMO, and showing signifcantly longer hospital stay with treatment. PSM did not fully match the patients, for example 65% of matched remdesivir patients were over 65, while only 55% of matched control patients were.
![]()
risk of death, 8.8% lower, RR 0.91, p = 1.00, treatment 9 of 74 (12.2%), control 26 of 195 (13.3%), PSM.
risk of mechanical ventilation or ECMO, 17.1% higher, RR 1.17, p = 0.76, treatment 4 of 74 (5.4%), control 9 of 195 (4.6%), PSM.
hospitalization time, 27.3% higher, relative time 1.27, p < 0.001, treatment 74, control 195, PSM.
Tsuzuki et al., 3/10/2021, retrospective, propensity score matching, Japan, Asia, preprint, 20 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Goldberg et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.029 (Peer Reviewed) |
hosp. time, ↓9.2%, p=0.77 |
A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in Israel |
|
Details
Retrospective 29 remdesivir patients and 113 controls, not finding a significant difference in nasopharyngeal viral load or hospitalization time. Hospitalization time was lower with treatment, with a larger reduction for non-intubated pat.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Goldberg et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.029 (Peer Reviewed) |
| A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary center in Israel |
Retrospective 29 remdesivir patients and 113 controls, not finding a significant difference in nasopharyngeal viral load or hospitalization time. Hospitalization time was lower with treatment, with a larger reduction for non-intubated patients, although not statistically significant in both cases.
![]()
hospitalization time, 9.2% lower, relative time 0.91, p = 0.77, treatment 29, control 113.
hospitalization time, 21.8% lower, relative time 0.78, p = 0.30, non-intubated patients only.
risk of no virological cure, 0.1% lower, RR 1.00, p = 0.98, treatment 29, control 113, relative change in Ct values.
Goldberg et al., 3/9/2021, retrospective, Israel, Middle East, peer-reviewed, 7 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) |
A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations |
|
Details
Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study, however authors suggest t.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Fateh et al., medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint) |
| A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations |
|
Retrospective 324 hospitalized patients in Iran reporting on the use Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations. There is no control group in this study, however authors suggest that Interferon β1a, corticosteroids, and remdesivir may not have a significant effect on mortality of hospitalization time.
Fateh et al., 3/8/2021, retrospective, Iran, Middle East, preprint, 7 authors.
|
|
Submit Corrections or Comments
|
|
Safety |
Touafchia et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.013 (Peer Reviewed) |
safety analysis |
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns |
|
Details
Comparison of bradycardia in COVID-19 patients treated with remdesivir compared to those treated with HCQ, lopinavir/ritonavir, tocilizumab or glucocorticoids, finding increased risk of bradycardia with remdesivir. |
|
Details
Source
PDF
Safety
Safety
|
| Touafchia et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.02.013 (Peer Reviewed) |
| Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns |
Comparison of bradycardia in COVID-19 patients treated with remdesivir compared to those treated with HCQ, lopinavir/ritonavir, tocilizumab or glucocorticoids, finding increased risk of bradycardia with remdesivir.
![]()
Touafchia et al., 2/27/2021, peer-reviewed, 6 authors.
|
|
Submit Corrections or Comments
|
|
N/A |
Shen et al., Fundamentals of Clinical Pharmacology, doi:10.1111/fcp.12643 (Peer Reviewed) |
safety analysis |
Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions |
|
Details
Analysis finding that remdesivir at nanomolar concentrations inhibits carboxylesterase‐2 (CES2) through covalent modifications. CES2 is a major drug‐metabolizing enzyme. Authors conclude that caution must be exercised when remdesivir is u.. |
|
Details
Source
PDF
N/A
N/A
|
| Shen et al., Fundamentals of Clinical Pharmacology, doi:10.1111/fcp.12643 (Peer Reviewed) |
| Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions |
|
Analysis finding that remdesivir at nanomolar concentrations inhibits carboxylesterase‐2 (CES2) through covalent modifications. CES2 is a major drug‐metabolizing enzyme. Authors conclude that caution must be exercised when remdesivir is used along with drugs hydrolyzed by CES2.
Shen et al., 12/28/2020, peer-reviewed, 3 authors.
|
|
Submit Corrections or Comments
|
|
In Vitro |
Jeffreys et al., bioRxiv, doi:10.1101/2020.12.23.424232 (Preprint) (In Vitro) |
in vitro |
Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2 |
|
Details
In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination. |
|
Details
Source
PDF
In Vitro
In Vitro
|
| Jeffreys et al., bioRxiv, doi:10.1101/2020.12.23.424232 (Preprint) (In Vitro) |
| Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2 |
|
In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.
Jeffreys et al., 12/24/2020, preprint, 15 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
|
|
Submit Corrections or Comments
|
|
Late |
Ullah et al., International Journal of Sciences, doi:10.18483/ijSci.2417 (Peer Reviewed) |
death, ↑100%, p=0.33 |
Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore |
|
Details
Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.
No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57... |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Ullah et al., International Journal of Sciences, doi:10.18483/ijSci.2417 (Peer Reviewed) |
| Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore |
Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57. Baseline oxygen requirement was 13.4 liters treatment vs. 10.8 control. Potential confounding by indication.
![]()
risk of death, 100% higher, RR 2.00, p = 0.33, treatment 8 of 30 (26.7%), control 4 of 30 (13.3%).
risk of mechanical ventilation, 250.0% higher, RR 3.50, p = 0.15, treatment 7 of 30 (23.3%), control 2 of 30 (6.7%).
Ullah et al., 11/29/2020, retrospective, Pakistan, South Asia, peer-reviewed, 8 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint) |
death, ↓20.0%, p=0.44 |
Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 |
|
Details
Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Garibaldi et al., medRxiv, doi:10.1101/2020.11.19.20234153 (Preprint) |
| Effectiveness of remdesivir with and without dexamethasone in hospitalized patients with COVID-19 |
Retrospective 303 remdesivir patients and 303 matched controls showing significantly faster clinical improvement, and lower (but not statistically significant) mortality.
risk of death, 20.0% lower, RR 0.80, p = 0.44, treatment 23 of 303 (7.6%), control 45 of 303 (14.9%), adjusted.
risk of no improvement at day 28, 35.0% lower, RR 0.65, p < 0.001, treatment 52 of 303 (17.2%), control 80 of 303 (26.4%), adjusted.
Garibaldi et al., 11/20/2020, retrospective, USA, North America, preprint, 10 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint) |
death, ↓48.9%, p=0.18 |
Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study |
|
Details
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant). |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Flisiak et al., medRxiv, doi:10.1101/2020.10.30.20215301 (Preprint) |
| Remdesivir-based therapy improved recovery of patients with COVID-19 in the SARSTer multicentre, real-world study |
Retrospective study comparing 122 remdesivir patients and 211 lopinavir/ritonavir patients, showing higher rates of clinical improvement with remdesivir and lower mortality (not statistically significant).
all patients, 48.9% lower, RR 0.51, p = 0.18, treatment 5 of 122 (4.1%), control 17 of 211 (8.1%), OR converted to RR.
SpO2<95%, 58.0% lower, RR 0.42, p = 0.13, treatment 4 of 82 (4.9%), control 14 of 119 (11.8%), OR converted to RR.
no clinical improvement, 56.5% lower, RR 0.44, p = 0.01, treatment 9 of 122 (7.4%), control 36 of 211 (17.1%), OR converted to RR.
Flisiak et al., 11/3/2020, retrospective, Poland, Europe, preprint, 23 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint) |
death, ↓47.0%, p<0.001 |
Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository |
|
Details
Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130 (Preprint) |
| Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository |
Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients showing 47% reduction in progression from ARDS to mortality.
risk of death, 47.0% lower, RR 0.53, p < 0.001, treatment 63 of 219 (28.8%), control 202 of 424 (47.6%), adjusted.
Solh et al., 10/20/2020, retrospective, database analysis, USA, North America, preprint, 5 authors.
|
|
Submit Corrections or Comments
|
|
Late |
SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15) (Peer Reviewed) |
death, ↓5.0%, p=0.53 |
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results |
|
Details
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50.
Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15) (Peer Reviewed) |
| Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results |
WHO SOLIDARITY open-label RCT with 2,750 very late stage (76% on oxygen/ventilation) Remdesivir patients, mortality relative risk RR 0.95 [0.81-1.11], p=0.50.Non-ventilated patients show a greater benefit, RR 0.86 [0.72-1.04], p = 0.13.
risk of death, 5.0% lower, RR 0.95, p = 0.53, treatment 301 of 2743 (11.0%), control 303 of 2708 (11.2%).
non-ventilated patients, 14.0% lower, RR 0.86, p = 0.13.
SOLIDARITY et al., 10/15/2020, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 15 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed) |
death, ↓27.0%, p=0.07 |
Remdesivir for the Treatment of Covid-19 — Final Report |
|
Details
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.
Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio H.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Beigel et al., NEJM, doi:10.1056/NEJMoa2007764 (Peer Reviewed) |
| Remdesivir for the Treatment of Covid-19 — Final Report |
RCT 1,062 hospitalized patients showing faster recovery time with treatment, median 10 days vs. 15 days for placebo, rate ratio for recovery 1.29, p<0.001.Day 29 mortality was 11.4% with remdesivir and 15.2% with placebo, hazard ratio HR 0.73 [0.52-1.03].
![]()
risk of death, 27.0% lower, RR 0.73, p = 0.07, treatment 541, control 521.
Beigel et al., 10/8/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 12 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268 (Peer Reviewed) |
death, ↓61.2%, p=0.02 |
Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States |
|
Details
Database analysis of 11,721 hospitalized patients, 48 treated with remdesivir.
Data inconsistencies have been found in this study, for example 99.4% of patients treated with HCQ were treated in urban hospitals, compared to 65% of untreat.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268 (Peer Reviewed) |
| Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States |
Database analysis of 11,721 hospitalized patients, 48 treated with remdesivir.Data inconsistencies have been found in this study, for example 99.4% of patients treated with HCQ were treated in urban hospitals, compared to 65% of untreated patients (Supplemental Table 3), while patients are distributed in a more balanced manner between teaching or not-teaching hospitals, as well as in the most urbanized (Northeast) and less urbanized (Midwest) regions of the United States [1].
risk of death, 61.2% lower, RR 0.39, p = 0.02, treatment 4 of 48 (8.3%), control 2510 of 11673 (21.5%), remdesivir vs. non-remdesivir.
risk of mechanical ventilation, 36.8% higher, RR 1.37, p = 0.25, treatment 11 of 48 (22.9%), control 1956 of 11673 (16.8%), remdesivir vs. non-remdesivir.
Fried et al., 8/28/2020, retrospective, database analysis, USA, North America, peer-reviewed, 11 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Pasquini et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321 (Peer Reviewed) |
death, ↓16.2%, p<0.0001 |
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU |
|
Details
Retrospective 51 ICU patients under mechanical ventilation, 25 treated with remdesivir, showing lower mortality with treatment. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Pasquini et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa321 (Peer Reviewed) |
| Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU |
Retrospective 51 ICU patients under mechanical ventilation, 25 treated with remdesivir, showing lower mortality with treatment.
![]()
risk of death, 16.2% lower, RR 0.84, p < 0.001, treatment 14 of 25 (56.0%), control 24 of 26 (92.3%), adjusted, OR converted to RR, multivariate.
Pasquini et al., 8/23/2020, retrospective, Italy, Europe, peer-reviewed, 9 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed) |
death, ↓34.9%, p=0.50 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial |
|
Details
Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.
5-day remdesivir had significantly higher odds of a better clinical status distribution on the.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Spinner et al., JAMA, doi:10.1001/jama.2020.16349 (Peer Reviewed) |
| Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial |
Late stage (median 8 days from symptom onset) RCT 584 patients with moderate COVID-19 showing (non-statistically significant) lower mortality.5-day remdesivir had significantly higher odds of a better clinical status distribution on the 7-point ordinal scale, odds ratio OR 1.65, p = 0.02. The difference for 10-day remdesivir was not statistically significant, p=0.18.
5 or 10 day remdesivir vs. control 28 day mortality, 34.9% lower, RR 0.65, p = 0.50, treatment 5 of 384 (1.3%), control 4 of 200 (2.0%).
Spinner et al., 8/21/2020, Randomized Controlled Trial, multiple countries, multiple regions, peer-reviewed, 30 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Olender et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041 (Peer Reviewed) |
death, ↓58.8%, p=0.001 |
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care |
|
Details
Comparative analysis between remdesivir trial GS-US-540–5773 and a retrospective SOC cohort with similar inclusion criteria, showing lower mortality and higher recovery at day 14 with remdesivir. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Olender et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041 (Peer Reviewed) |
| Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care |
Comparative analysis between remdesivir trial GS-US-540–5773 and a retrospective SOC cohort with similar inclusion criteria, showing lower mortality and higher recovery at day 14 with remdesivir.
![]()
risk of death, 58.8% lower, RR 0.41, p = 0.001, treatment 24 of 312 (7.7%), control 102 of 818 (12.5%), OR converted to RR, day 14, weighted multivariable logistic regression.
Olender et al., 7/24/2020, retrospective, USA, North America, peer-reviewed, 33 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Dubert et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.093 (Peer Reviewed) |
Case report study of the first five COVID-19 patients treated with remdesivir in France |
|
Details
Early report on 5 ICU patients treated with remdesivir highlighting issues with usage in critically ill patients. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Dubert et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.093 (Peer Reviewed) |
| Case report study of the first five COVID-19 patients treated with remdesivir in France |
|
Early report on 5 ICU patients treated with remdesivir highlighting issues with usage in critically ill patients.
Dubert et al., 6/30/2020, peer-reviewed, 15 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531
(Preprint) (meta analysis) |
death, ↓36.0%, p=0.02 |
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials |
|
Details
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175). |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531
(Preprint) (meta analysis) |
| Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials |
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).
![]()
risk of death, 36.0% lower, RR 0.64, p = 0.02.
Zhu et al., 6/29/2020, preprint, 11 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed) |
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 |
|
Details
RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment.
NCT04292899 |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Goldman et al., NEJM, doi:10.1056/NEJMoa2015301 (Peer Reviewed) |
| Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 |
RCT of remdesivir for 5 or 10 days with no placebo control group, showing no significant differences between 5 and 10 day treatment.NCT04292899
![]()
Goldman et al., 5/27/2020, peer-reviewed, 26 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed) |
death, ↑8.6%, p=1.00 |
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial |
|
Details
Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.
While too small for significance, the subgroup treated within 10 days.. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Wang et al., Lancet, doi:10.1016/S0140-6736(20)31022-9 (Peer Reviewed) |
| Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial |
Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.While too small for significance, the subgroup treated within 10 days showed reduced mortality RR 0.76, p = 0.58, and reduced median time to clinical improvement of 18 days vs. 23 days, hazard ratio 1.52 [0.95-2.43].
![]()
all patients, 8.6% higher, RR 1.09, p = 1.00, treatment 22 of 158 (13.9%), control 10 of 78 (12.8%).
<10 days from symptoms, 24.3% lower, RR 0.76, p = 0.58, treatment 8 of 71 (11.3%), control 7 of 47 (14.9%).
>10 days from symptoms, 47.6% higher, RR 1.48, p = 0.76, treatment 12 of 84 (14.3%), control 3 of 31 (9.7%).
Wang et al., 4/29/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 46 authors.
|
|
Submit Corrections or Comments
|
|
Late |
Grein et al., NEJM, doi:10.1056/NEJMoa2007016 (Peer Reviewed) |
Compassionate Use of Remdesivir for Patients with Severe Covid-19 |
|
Details
Report on compassionate use of remdesivir with 61 severe COVID-19 patients, showing clinical improvement in 36 of 53 patients. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Grein et al., NEJM, doi:10.1056/NEJMoa2007016 (Peer Reviewed) |
| Compassionate Use of Remdesivir for Patients with Severe Covid-19 |
Report on compassionate use of remdesivir with 61 severe COVID-19 patients, showing clinical improvement in 36 of 53 patients.
![]()
Grein et al., 4/10/2020, peer-reviewed, 59 authors.
|
|
Submit Corrections or Comments
|
